$1,000 follows their calls into $1,000
- Win rate
- 0%
- Streak
- —
- Best call
- No call read in the last 30 days
Track record building
- Peak #201
- 6 ranked closes
- Longest streak 6
$1,000 follows their calls into $1,000
The Small Pond@TheSmallPond_An undeniable truth of stocks is that valuation vs growth is the only thing that matters. Valuation is your friend or it can be your worst enemy. Even if I try to guide every investment decision by this principle, there’s been times when I overlooked this in favor of a good
The Small Pond@TheSmallPond_So you’re telling me $SPCX needs to deploy billions in capital just to catch up with 3 incumbents to enter a 120% penetrated and undifferentiated market and this is supposed to get me excited?
The Small Pond@TheSmallPond_$OKTA at $155 now. Thesis remains the same. Thanks IBM
The Small Pond@TheSmallPond_I think $OKTA still has room to run. Stock is up 44% since management upgraded FY27 rev guidance from 9% to 9%-10%, but Street revenue and EPS estimates for the next 2 years haven’t moved an inch. Okta’s average ACV jumps +40% when you upsell to include agentic AI security. If

The Small Pond@TheSmallPond_Stay away from people like this like the plague. Because what could go wrong at 25x sales? @peter_mantas the only real person I know that has been calling out $TWST since it was an undiscovered gem.
Freda Duan@FredaDuanAI Drug Discovery Is Becoming a Bottleneck Trade I get excited when an industry starts going through a real regime change. AI drug discovery (“AIDD”) increasingly looks like one of those moments. Two things are happening: 1/ Upstream: the frontier AI labs are piling in. 2/


The Small Pond@TheSmallPond_While the JV model offers the financing benefit and this is the way to do business because countries need localization, I also see important downsides. JVs are pretty common among defense primes, but primes are large companies where equity-method accounted net results represent
PhotonBull@PhotonBullThe most underrated development in space and defense right now is the shift from export sales to equity joint ventures. $ASTS and $EOS.AX are both running a similar playbook and the market has not fully priced what it means. $ASTS and Rakuten are forming an equal stakes JV this
